Ballentine Partners LLC lifted its stake in shares of Medtronic plc. (NYSE:MDT) by 33.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,239 shares of the medical technology company’s stock after acquiring an additional 2,065 shares during the period. Ballentine Partners LLC’s holdings in Medtronic were worth $641,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of MDT. BlackRock Inc. raised its holdings in shares of Medtronic by 2,513.4% during the 1st quarter. BlackRock Inc. now owns 87,035,376 shares of the medical technology company’s stock worth $7,011,571,000 after acquiring an additional 83,705,052 shares during the period. Lazard Asset Management LLC raised its holdings in shares of Medtronic by 1,061.4% during the 1st quarter. Lazard Asset Management LLC now owns 13,678,772 shares of the medical technology company’s stock worth $1,101,960,000 after acquiring an additional 12,500,992 shares during the period. Vanguard Group Inc. raised its holdings in shares of Medtronic by 4.5% during the 1st quarter. Vanguard Group Inc. now owns 102,321,656 shares of the medical technology company’s stock worth $8,243,034,000 after acquiring an additional 4,412,536 shares during the period. Alliancebernstein L.P. raised its holdings in shares of Medtronic by 135.5% during the 2nd quarter. Alliancebernstein L.P. now owns 6,070,160 shares of the medical technology company’s stock worth $538,727,000 after acquiring an additional 3,493,058 shares during the period. Finally, American Century Companies Inc. raised its holdings in Medtronic by 35.0% in the 3rd quarter. American Century Companies Inc. now owns 9,082,452 shares of the medical technology company’s stock valued at $706,342,000 after buying an additional 2,354,467 shares during the period. Institutional investors and hedge funds own 81.74% of the company’s stock.

In other news, EVP Bryan C. Hanson sold 16,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $79.02, for a total transaction of $1,264,320.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have sold 48,000 shares of company stock valued at $3,837,920. Corporate insiders own 0.31% of the company’s stock.

Several brokerages recently issued reports on MDT. BMO Capital Markets boosted their price objective on shares of Medtronic to $94.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. SunTrust Banks restated a “buy” rating and issued a $96.00 price objective on shares of Medtronic in a report on Monday, October 2nd. Jefferies Group restated a “buy” rating and issued a $96.00 price objective on shares of Medtronic in a report on Thursday, September 28th. Argus upgraded shares of Medtronic from a “hold” rating to a “buy” rating and boosted their price objective for the company from $81.27 to $95.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. Finally, UBS restated an “overweight” rating on shares of Medtronic in a report on Thursday, August 24th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Medtronic currently has a consensus rating of “Hold” and a consensus price target of $88.57.

Shares of Medtronic plc. (MDT) opened at $83.43 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.05 and a current ratio of 2.40. The stock has a market cap of $113,017.08, a PE ratio of 18.00, a price-to-earnings-growth ratio of 2.30 and a beta of 1.00. Medtronic plc. has a one year low of $69.35 and a one year high of $89.72.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.08. The company had revenue of $7.05 billion for the quarter, compared to analyst estimates of $7.05 billion. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.12 earnings per share. sell-side analysts anticipate that Medtronic plc. will post 4.77 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 19th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.46 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.84 dividend on an annualized basis and a yield of 2.21%. Medtronic’s dividend payout ratio (DPR) is presently 50.41%.

TRADEMARK VIOLATION NOTICE: “Ballentine Partners LLC Has $641,000 Stake in Medtronic plc. (MDT)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/ballentine-partners-llc-has-641000-stake-in-medtronic-plc-mdt/1772670.html.

Medtronic Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.